Possible role of purinergic signaling in COVID-19

被引:32
作者
Franciosi, Maria Luiza Mukai [1 ]
Lima, Millena Daher Medeiros [1 ]
Schetinger, Maria Rosa Chitolina [2 ]
Cardoso, Andreia Machado [3 ]
机构
[1] Fed Univ Fronteira Sul, Med Course, Campus Chapeco, Chapeco, SC, Brazil
[2] Univ Fed Santa Maria, Postgrad Program Biol Sci Toxicol Biochem, CCNE, Santa Maria, RS, Brazil
[3] Fed Univ Fronteira Sul, Grad Program Biomed Sci, Med Course, Brazilian Purine Club, Campus Chapeco,Rodovia SC 484 Km 02, BR-89815899 Chapeco, SC, Brazil
关键词
Purinergic Signaling; COVID-19; Ectonucleotidases; ATP; Adenosine; RECEPTOR AGONISM; P2X7; RECEPTOR; THROMBOSIS; INFLAMMATION; PATHWAY; SYSTEM;
D O I
10.1007/s11010-021-04130-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The coronavirus disease (COVID-19), caused by SARS-CoV-2 infection, accounts for more than 2.4 million deaths worldwide, making it the main public health problem in 2020. Purinergic signaling is involved in the pathophysiology of several viral infections which makes the purinergic system a potential target of investigation in COVID-19. During viral infections, the ATP release initiates a cascade that activates purinergic receptors. This receptor activation enhances the secretion of pro-inflammatory cytokines and performs the chemotaxis of macrophages and neutrophils, generating an association between the immune and the purinergic systems. This review was designed to cover the possible functions of purinergic signaling in COVID-19, focusing on the possible role of purinergic receptors such as P2X7 which contributes to cytokine storm and inflammasome NLRP3 activation and P2Y1 that activates the blood coagulation pathway. The possible role of ectonucleotidases, such as CD39 and CD73, which have the function of dephosphorylating ATP in an immunosuppressive component, adenosine, are also covered in detail. Moreover, therapeutic combination or association possibilities targeting purinergic system components are also suggested as a possible useful tool to be tested in future researches, aiming to unveil a novel option to treat COVID-19 patients.
引用
收藏
页码:2891 / 2898
页数:8
相关论文
共 55 条
[1]   Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis [J].
Abouelkhair, Mohamed A. .
MEDICAL HYPOTHESES, 2020, 144
[2]   Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [J].
Ackermann, Maximilian ;
Verleden, Stijn E. ;
Kuehnel, Mark ;
Haverich, Axel ;
Welte, Tobias ;
Laenger, Florian ;
Vanstapel, Arno ;
Werlein, Christopher ;
Stark, Helge ;
Tzankov, Alexandar ;
Li, William W. ;
Li, Vincent W. ;
Mentzer, Steven J. ;
Jonigk, Danny .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) :120-128
[3]   Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73-Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes [J].
Ahmadi, Parimah ;
Hartjen, Philip ;
Kohsar, Matin ;
Kummer, Silke ;
Schmiedel, Stefan ;
Bockmann, Jan-Hendrik ;
Fathi, Anahita ;
Huber, Samuel ;
Haag, Friedrich ;
Schulze zur Wiesch, Julian .
CELLS, 2020, 9 (08) :1-16
[4]   Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome [J].
Ali, Ramadan A. ;
Gandhi, Alex A. ;
Meng, He ;
Yalavarthi, Srilakshmi ;
Vreede, Andrew P. ;
Estes, Shanea K. ;
Palmer, Olivia R. ;
Bockenstedt, Paula L. ;
Pinsky, David J. ;
Greve, Joan M. ;
Diaz, Jose A. ;
Kanthi, Yogendra ;
Knight, Jason S. .
NATURE COMMUNICATIONS, 2019, 10 (1)
[5]   The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases [J].
Antonioli, Luca ;
Blandizzi, Corrado ;
Pacher, Pal ;
Hasko, Gyorgy .
PHARMACOLOGICAL REVIEWS, 2019, 71 (03) :345-382
[6]   Adenosine signaling and the immune system: When a lot could be too much [J].
Antonioli, Luca ;
Fornai, Matteo ;
Blandizzi, Corrado ;
Pacher, Pal ;
Hasko, Gyorgy .
IMMUNOLOGY LETTERS, 2019, 205 :9-15
[7]   Tuning the Thromboinflammatory Response to Venous Flow Interruption by the Ectonucleotidase CD39 [J].
Anyanwu, Anuli C. ;
Kanthi, Yogendra ;
Fukase, Keigo ;
Liao, Hui ;
Mimura, Tekashi ;
Desch, Karl C. ;
Gruca, Martin ;
Kaskar, Saabir ;
Sheikh-Aden, Hussein ;
Chi, Liguo ;
Zhao, Raymond ;
Yadav, Vinita ;
Wakefield, Thomas W. ;
Hyman, Matthew C. ;
Pinsky, David J. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) :E118-E129
[8]   A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases [J].
Arulkumaran, Nishkantha ;
Unwin, Robert J. ;
Tam, Frederick W. K. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) :897-915
[9]   Severe Covid-19 [J].
Berlin, David A. ;
Gulick, Roy M. ;
Martinez, Fernando J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2451-2460
[10]   The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression [J].
Burnstock, Geoffrey ;
Knight, Gillian E. .
PURINERGIC SIGNALLING, 2018, 14 (01) :1-18